Skip to main content
Premium Trial:

Request an Annual Quote

FDA Approves FoundationOne CDx for Takeda's ALK-Inhibitor

NEW YORK – Foundation Medicine said on Thursday that the US Food and Drug Administration has approved the company's tissue-based, next-generation sequencing test, FoundationOne CDx, as a companion diagnostic for Takeda's FDA-approved non-small cell lung cancer treatment brigatinib (Alunbrig).

The approval comes after Roche subsidiary Foundation Medicine and Takeda inked a deal last year to develop companion diagnostics for Takeda's NSCLC agents. Brigatinib has been FDA-approved to treat ALK-positive NSCLC patients who are refractory to crizotinib (Pfizer's Xalkori) since 2017, and it is approved as a first-line treatment for ALK-positive NSCLC since last year. At the time of brigatinib's first-line FDA approval, the agency approved Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit as a companion diagnostic.

FDA's decision to approve FoundationOne CDx as a companion diagnostic for brigatinib, according to Foundation Medicine, reflects a recognition that ALK rearrangements can be overlooked with alternative non-NGS testing methods. FoundationOne CDx, which detects substitutions, insertion and deletion alterations, copy number alterations in 324 genes, and select gene rearrangements, now has a total of 28 companion diagnostic claims.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.